Overview

* NeuroPace Inc ( NPCE ) Q2 revenue grows 22% yr/yr to $23.5 mln, beating estimates

* Company raises full-year 2025 revenue guidance to $94-$98 mln

* Gross margin improves to 77.1% driven by manufacturing efficiencies

Outlook

* NeuroPace ( NPCE ) raises 2025 revenue guidance to $94 mln-$98 mln

* Company increases 2025 gross margin guidance to 75%-76%

Result Drivers

* RNS SYSTEM SALES - Revenue growth driven by increased sales of the RNS System

* MANUFACTURING EFFICIENCIES - Strong gross margin of 77.1% attributed to manufacturing efficiencies and positive product mix

* PROJECT CARE MOMENTUM - Increased contribution from Project CARE in Q2 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $23.52 $23.10

Revenue mln mln (8

Analysts

)

Q2 EPS -$0.26

Q2 Net -$8.65

Income mln

Q2 Gross $18.13

Profit mln

Q2 -$6.82

Income mln

from

Operatio

ns

Q2 $24.96

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Neuropace Inc ( NPCE ) is $17.00, about 47.7% above its August 11 closing price of $8.89

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)